Pimobendan in Cats: What the HCM and Congestive Heart Failure Evidence Actually Shows
A 2014 retrospective study reported a median survival of 626 days in cats with congestive heart failure (CHF) from hypertrophic cardiomyopathy (HCM) who received pimobendan, against 103 days in matched cats who did not. A 2021 prospective, randomized, placebo-controlled study of cats with HCM and recent CHF found no benefit on 180-day outcome. The two results are not simply in conflict. They answer different questions in different cats, and neither is a US label.
Why the studies seem to disagree
The retrospective study (Reina-Doreste and colleagues, J Am Vet Med Assoc, 2014) reviewed records from 2003 to 2013 and compared 27 cats given pimobendan with 27 CHF cats treated without it. The control cats were matched on age, sex, body weight, type of cardiomyopathy and manifestation of CHF. It measured survival from the first CHF diagnosis. The authors concluded that adding pimobendan to traditional CHF treatment may provide a substantial survival benefit, and they described this as a case-control finding.
The prospective study (Schober and colleagues, J Vet Intern Med, 2021) enrolled 83 cats with HCM and recently controlled CHF. Of these, 30 had left ventricular outflow tract obstruction (LVOTO) and 53 did not. Cats received pimobendan (n = 43), placebo (n = 39) or no medication (n = 1), together with furosemide with or without clopidogrel. Success meant completing 180 days without a furosemide dose increase. The proportion with a successful outcome did not differ between groups (P = .75), and the study identified no benefit of pimobendan on 180-day outcome.
Neither design can settle the other's question. A retrospective comparison can carry hidden differences between treated and untreated cats. A 180-day exploratory study with a furosemide-escalation endpoint may not detect a survival difference that occurs over a longer period or in other cats. The authors called their study nonpivotal and exploratory.
Evidence ledger by population and design
The Ward study and the two acute pharmacodynamic studies address safety and short-term effects. They do not show that treatment changes how long a cat lives or how well it does.
Why HCM is not one situation
The ACVIM consensus statement classifies feline cardiomyopathy by phenotype and stage. In its staging system, stage B is subclinical disease, divided into B1 (lower risk of imminent CHF or arterial thromboembolism) and B2 (higher risk). Stage C describes cats that have developed CHF or thromboembolism, even if signs resolve with treatment, and stage D describes CHF that does not respond to treatment. A cat's stage therefore changes which study resembles it.
Outflow tract obstruction is another dividing line. The consensus statement notes that dynamic left ventricular outflow tract obstruction does not appear to be a poor prognostic factor in cats, in contrast to people. It also says that the diuretic needs of cats with CHF are similar regardless of the form of cardiomyopathy. Obstruction nevertheless matters for pimobendan because the consensus recommendations are conditional on its absence, and the Schober subgroup results ran in opposite directions with wide uncertainty. The 2025 review adds that pimobendan is contraindicated in cats with fixed obstructions of the left or right ventricular outflow tract, as seen in congenital aortic or pulmonic stenosis.
Underlying causes also need to be checked. The consensus statement recommends measuring blood pressure and thyroxine in cats with a hypertrophic phenotype, because hypertension and hyperthyroidism can produce or worsen the same appearance on the echocardiogram.
What the US label does and does not say
Pimobendan has FDA-approved products for dogs. FDA approved Vetmedin Solution (pimobendan oral solution) for dogs in February 2024, for managing the signs of mild, moderate or severe CHF due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy. Vetmedin chewable tablets carry the same CHF indication, and in December 2025 FDA supplemented their approval with an indication to delay onset of CHF in dogs with Stage B2 preclinical MMVD. Those indications describe canine heart disease and do not transfer to cats.
The 2025 review states that no pimobendan formulations have been approved for use in cats, and that approved oral solutions in the US and other markets are for dogs. VCA's veterinary reference page also describes use in cats to treat heart failure as off-label. The manufacturer's description of its canine products says they are for dogs with clinical evidence of heart failure and should not be given in hypertrophic cardiomyopathy, aortic stenosis, or any condition where augmenting cardiac output is inappropriate. That statement concerns dogs, but it shows why a cat with HCM calls for individual veterinary judgment rather than reasoning from a dog product.
Off-label use means a veterinarian directs a use that the label does not describe, within a valid veterinarian-client-patient relationship. FDA states that a compounded pimobendan product is not FDA-approved.
Questions to bring to the cardiology visit
The studies above are a way to match your cat to the evidence, not to select treatment. These questions help the veterinarian place your cat.
-
What is my cat's diagnosis and phenotype, and was it confirmed by echocardiography, ideally by a specialist?
-
Which stage is my cat: subclinical (B1 or B2), CHF (C), or CHF that no longer responds well (D)?
-
Has my cat had CHF recently, and was it controlled before any new medication?
-
Is there outflow tract obstruction, and is it dynamic or fixed? How does that affect the options?
-
Have blood pressure and thyroid hormone been checked, and could another disease explain the heart changes?
-
Does my cat's situation resemble the cats in the retrospective study, the prospective study, or the short-term studies?
-
What are we trying to achieve, such as fewer episodes of fluid in the lungs, easier breathing, longer survival, or a longer time between diuretic dose increases?
-
If pimobendan is considered, which exact product and source will be used, and is it an off-label prescription?
-
What follow-up will we use, and which changes should prompt a call?
Labored or open-mouth breathing, collapse, or sudden weakness or paralysis of the hind limbs needs urgent veterinary care. The consensus statement notes that labored breathing is the most common presenting sign of CHF in cats, and paresis or paralysis is a common sign of arterial thromboembolism. These signs should not wait for a scheduled visit.
The conversation is complete when you can say which study looks like your cat, what the label does not cover, and which of the questions above remain open for the veterinarian to answer.